

*Disclaimer :*

*The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.*

**M.10629 - CSL / VIFOR PHARMA**

**SECTION 1.2**

**Description of the concentration**

1. The Commission has received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (the “**EUMR**”). On 26 April 2022, CSL Limited (“**CSL**”) notified its intention to acquire sole control of Vifor Pharma Ltd. (“**Vifor Pharma**”) by way of a public tender offer pursuant to a transaction agreement entered into by CSL and Vifor Pharma on 14 December 2021.
2. The areas of activities of the undertakings concerned by the notified concentration are as follows:
  - a) CSL is an Australian-based biotechnology company with a portfolio of life-saving medicines, including those that treat hemophilia and immune deficiencies (through CSL Behring), as well as vaccines to prevent influenza (through Seqirus). In addition, CSL Plasma, a division of CSL Behring, operates a plasma collection network.
  - b) Vifor Pharma is a Swiss-based pharmaceutical company active worldwide in the development, manufacturing, and marketing of pharmaceutical products for the treatment of iron deficiency, nephrology (kidney care), and cardio-renal therapies.